The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.

Condition	Treatment or Intervention	Phase
Secondary Hyperparathyroidism End Stage Renal Disease	Drug: paricalcitol injection	Phase IV

Further Study Details: 

Expected Total Enrollment:  28

Ages Eligible for Study:  2 Years   -   20 Years,  Genders Eligible for Study:  Both

Criteria

Subjects ages 2-20 with ESRD on hemodialysis with Secondary hyperparathyroidism

California
      Stanford University Medical Center, Stanford,  California,  94305,  United States
Florida
      Miami Children's Hospital, Miami,  Florida,  United States
New York
      The Children's Hospital of Buffalo, Buffalo,  New York,  United States
Texas
      Texas Children's Hospital, Houston,  Texas,  United States
      University of Texas at Houston, Houston,  Texas,  United States
Wisconsin
      Medical College of Wisconsin, Milwaukee,  Wisconsin,  United States

Study chairs or principal investigators

Dheerendra Kommala, M.D.,  Abbott Laboratories   

Study ID Numbers:  2001-022
Record last reviewed:  October 2003
Last Updated:  October 13, 2004
Record first received:  January 30, 2003
ClinicalTrials.gov Identifier:  NCT00053547
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08